Adjuvant immunochemotherapy for the 3 participants was administered based on the following reasons: 1) extremely low EGFR mutant abundance in the resected tumor tissue; 2) diagnosis of double primary tumors harboring EGFR and KRAS mutations, respectively, postoperatively; 3) primary Afatinib resistance. Here, KRAS is linked to neoplasm.